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Introduction
Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic subtypes of breast cancer and the molecular subtypes found in other solid tumors. The molecular subtypes in other solid tumors are enriched with specific mutations and copy number aberrations (CNAs) that are thought to underlie their distinct progression patterns, and biological and clinical properties.
Evidence acquisition
We used the complete The Cancer Genome Atlas (TCGA) RNA-seq dataset and three different published classifiers developed by our groups to assign TCGA's bladder cancers to molecular subtypes, and examined the prevalence of the most common DNA alterations within them (Supplementary material). We interpreted the results against the background of what was known from the published literature about the prevalence of these alterations in nonmuscle-invasive and muscle-invasive bladder cancers.
Evidence synthesis
Clinical issues in bladder cancer
Clinical experience and emerging genomic data support the idea that bladder cancers progress along two largely nonoverlapping tracks (''papillary'' and ''nonpapillary'') that pose distinct challenges for clinical management [1] [2] [3] . Most nonmuscle-invasive bladder cancers (NMIBCs) belong to the papillary pathway and are characterized by the presence of activating type-3 receptor for fibroblast growth factor (FGFR3) mutations, downstream Ras pathway activation, wild-type TP53, and stable genomes [1] [2] [3] . Clinically, papillary NMIBCs are rarely lethal but recur almost always, necessitating that patients receive lifelong surveillance; the repeated surgical procedures required to deal with recurrences cause significant anxiety, discomfort, and morbidity, making bladder cancer the most expensive tumor on a per patient basis. A significant proportion of cases (15-20%) of NMIBCs progress to become muscle invasive [1, 2] . However, currently no reliable tools are available to identify them before they become life threatening. The nonpapillary pathway is characterized by loss-of-function mutations and CNAs involvingTP53 and RB1 and genomic instability [1, 2] . It gives rise to aggressive, muscle-invasive bladder cancers (MIBCs), representing approximately 20-25% of all bladder cancers and causing death in approximately half of affected patients. Carcinoma in situ (CIS) is generally considered to be the precursor lesion for nonpapillary MIBCs [1, 2] , but comprehensive genomic data for CIS are not yet available, so this assumption awaits direct experimental validation. Patients with either high-grade papillary nonmuscle-invasive disease or CIS are currently treated with the same adjuvant therapy (intravesical Bacillus Calmette-Guerin [BCG] immunotherapy), but it is by no means clear that BCG produces comparable benefit in CIS and high-grade papillary tumors [1, 2] . Many high-grade papillary tumors ultimately become BCG unresponsive, so clinicians are then faced with the dilemma of whether to continue using a bladder-sparing regimen or to employ definitive surgery. The latter is certainly too aggressive for those patients whose tumors could be controlled by local therapy, but again there are no reliable tools to distinguish the tumors that have the potential to metastasize from those that do not. Muscle-invasive disease is managed with definitive local therapy (chemoradiation) or surgery (cystectomy) with or without perioperative systemic cisplatin-based chemotherapy to treat subclinical metastatic disease, but it is still not possible to distinguish the patients who warrant chemotherapy from those who will not benefit from it. It would also be tremendously useful to have biomarkers that would enable patients and their physicians to choose between bladder-sparing regimens such as chemoradiation and cystectomy. Overall, it is hoped that by understanding the molecular mechanisms that give rise to papillary and nonpapillary bladder cancers, it will be possible to develop methods to inform clinical decision making at every step of disease progression and management.
Intrinsic subtypes of cancer
The widespread use of genomics to investigate cancer heterogeneity is transforming our understanding of cancer biology. A pioneering study in leukemia demonstrated that mRNA expression profiling could be used to distinguish ALL from AML with a high degree of accuracy [4] , and a subsequent study used gene expression profiling to identify two previously unrecognized molecular subtypes of diffuse large B-cell lymphoma [5] . Importantly, patients whose tumors belonged to one of the subtypes (''germinal centerlike DLBCL'') had better clinical outcomes than patients with the other (''activated B-like DLBCL'') [5] . Parallel studies in breast cancer revealed that they could also be grouped into ''intrinsic subtypes'' that had very different biological properties and behaved clinically as distinct disease entities [6, 7] . . Although the biological consequences of these events have not been defined experimentally, they would be expected to lead to decreased RNA polymerase accessibility, gene silencing, and a less well-differentiated phenotype. In-depth chromatin immunoprecipitation/sequencing (ChIP-seq) studies are required to directly address this hypothesis.
As introduced above, one of the most striking differences between NMIBCs and MIBCs is the relative frequency of TP53 gene inactivation and relative levels of genomic instability. Overall, mutations in TP53 were observed in about 50% of MIBCs but were less common in NMIBCs ( Bladder cancers often contained DNA alterations involving oncogenes or tumor suppressor genes that regulate activation of the Ras-MEK-ERK and PI3 kinase-AKT-mTOR pathways. These pathways control progression through the RB1-dependent G1-S cell cycle restriction point, anabolic metabolism, and cell survival. Activating mutations in Fisher's exact test was used to determine differences between subtypes. CNA = copy number aberration; UNC = University of North Carolina. * p < 0.05 was considered significant.
We then used the top 30 most prevalent mutations and CNAs in TCGA's whole exome sequencing dataset in Firehose and cBioportal, respectively, and examined their prevalence in the UNC basal-like and luminal subtypes (Supplementary Fig. 1 and 2 ). Included among them were alterations that were enriched in the breast cancer intrinsic subtypes (TP53, RB1, ERBB2, and PIK3CA), genes that displayed different mutation frequencies in NMIBCs versus MIBCs (FGFR3, KDM6A, and STAG2), and genes that encode for mRNAs that were enriched in basal or luminal MIBCs (EGFR, PPARG, GATA3, ELF3, and ERBB3). Consistent with the overall hypothesis, several of the alterations were significantly enriched in either UNC basal-like or luminal cancers (Fig. 2) .
We then investigated whether creating further subdivisions of the UNC molecular subtypes caused additional patterns of enrichment as had been documented previously
Although the mutations and CNAs that were enriched in the UNC basal-like and luminal MIBCs were also enriched in the MD Anderson basal and luminal MIBCs, isolating the p53-like tumors did not further enhance enrichment (Fig. 3) . Similarly, no mutations or CNAs were specifically enriched in the Lund infiltrated tumors as compared with the other Lund subtypes in this panel (Fig. 4) . Therefore, it appears that the biology of these infiltrated tumors is dictated less by genetic influences than by other factors, such as the tumor microenvironment, explaining why their subtype membership was somewhat unstable [ [ 7 , and the uroB tumors also contained a higher number of CDKN2A (p16) deletions (Fig. 4) . The uroA and uroB tumors were also characterized by fewer RB1 mutations, and the uroB tumors could be distinguished from the uroA tumors by their content of PIK3CA, NFE2L2, ERBB2, and ERBB3 mutations (Fig. 4) . and amplification of PPARG, GATA3, ERBB2, and E2F3/SOX4 (Fig. 4) . were also enriched in luminal cancers. Biological effects of these alterations will need to be explored in future functional studies. The Lund subclassifications divide the UNC/MD Anderson/TCGA basal/SCC-like and luminal subtypes in ways that have important biological and clinical implications. Although they cluster together with the squamous/basal tumors in the UNC, MD Anderson, and TCGA classifications, the genetic alterations in the uroB tumors more closely resemble those present in the luminal uroA subtype, supporting the conclusion that they represent progressed versions of the uroA cancers. The precise mechanisms that cause them to appear more ''basal'' (at the molecular level, and also in terms of their enrichment with squamous histological features and lethality) will be very interesting; their relatively high content of RB1 and NFE2L2 mutations suggests possible mechanisms. The existence of uroB tumors also suggests that basal versus luminal subtype class ''switching'' is possible. Clinically, it will be interesting to determine whether the uroA and uroB tumors are equally sensitive to FGFR inhibitors. Fisher's exact test was used to determine differences between subtypes. CNA = copy number aberration; GU = genomically unstable; Infil = infiltrated; SCCL = squamous cell carcinoma like; uroA = urobasal A; uroB = urobasal B. * p < 0.05 was considered significant.
Conclusions
The subdivision in the UNC/MD Anderson/TCGA luminal tumors that is created by the Lund classifier also appears to be extremely important. It is very interesting that the GU and uroA tumors are enriched with somewhat mutually exclusive patterns of mutations and CNAs involving key luminal genes (PPARG/GATA3 vs FGFR3). Overall, more of the top genes in the GU tumors were affected by CNAs than they were in the other molecular subtypes. The fact that GU tumors are enriched with ERCC2 mutations is also noteworthy. It will be interesting to determine their relationships to cigarette smoking It should be emphasized that our understanding of the biological and clinical properties of the molecular subtypes of bladder cancer is still fairly limited. Most of the available genomic and associated clinical data were obtained retrospectively, and the clinical follow-up is fairly short. Although the total number of profiled bladder cancers is increasing, it is relatively small, and challenges associated with merging the data that have been and continue to be generated on different genomic platforms make generating meta-datasets difficult. The specific effects of most of the DNA alterations that have been identified in bladder cancers need to be explored much more deeply, presumably in preclinical models, to determine whether subtype context is important for their effects. The new information provided by TCGA and other groups will enable laboratory scientists to create models that more accurately capture important aspects of the genomic heterogeneity observed in patients.
We . In addition, as noted above, the uroB subtype may establish a precedent for luminal-to-basal subtype ''switching'' in bladder cancer. Muscle-invasive tumors can be multifocal, and our collaborators are currently performing wholeorgan mapping studies to determine whether all these multifocal tumors belong to the same subtype (B. Czerniak, personal communication). NMIBCs are prone to recurrence, and it will be important to perform longitudinal studies to determine how often subtype membership is maintained in these recurrences. Ongoing studies are performing deep genomic characterizations of metastases, and it will be interesting to see whether primary tumors and metastases always belong to the same subtype. Finally, additional comparisons of the DNA alterations in and subtype membership of tumors collected before and after neoadjuvant therapies, and where possible, systemic therapy for metastatic disease, must still be performed to determine whether subtype membership is stable. This information has important implications for prognostication and subtype-based therapy.
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